Kovina Therapeutics Inc.
Indianapolis, IN
- UEI
- YBFLBP3NTM27
- CAGE
- 8VM57
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1210 Waterway Blvd #2000, Indianapolis, IN 46202, USA
- Website
- kovina.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Emmune Inc. | Cambridge, MA | — |
| Privo Technologies, Inc. | Peabody, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Atila Biosystems Incorporated | Sunnyvale, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Sales | Irvine, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Immunova Therapeutics LLC | Monrovia, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Kovina Therapeutics Inc., a for-profit biotech company based in Indianapolis, Indiana, is a federal grant recipient focused on the discovery and development of small-molecule therapeutics targeting human papillomavirus (HPV) infections and HPV-associated cancers. The company operates exclusively as a prime recipient on National Institutes of Health grant awards, with no federal contracts or subcontract engagements in the source data.
Kovina's federal grant work centers on the design and synthesis of covalent HPV-16 E6 inhibitors — small molecules that bind to the HPV-16 E6 oncoprotein and block its interaction with the E6AP ubiquitin ligase, thereby restoring tumor suppressor protein P53 function selectively in HPV-positive cells. Representative work includes a $1,143,891 National Cancer Institute award (CFDA 93.395, Cancer Treatment Research program) issued August 14, 2026, to develop novel therapeutics for HPV-associated oropharyngeal, cervical, and anogenital cancers, running through July 31, 2028; a $1 million National Institute of Dental and Craniofacial Research award issued September 1, 2022, targeting small-molecule E6 inhibitors for oropharyngeal cancers; and a National Institute of Allergy and Infectious Diseases award issued July 1, 2022, focused on dysplasia treatment across cervical, genital, and anal sites. Kovina also received an earlier National Cancer Institute Small Business Technology Transfer (STTR) award issued March 1, 2022, characterizing pharmacokinetic properties of E6 inhibitors and advancing lead candidates toward IND-enabling studies, with mentorship from the company's CEO and board chair on corporate drug development and biotech company management.
Kovina's customer base is entirely within the National Institutes of Health, with three distinct institutes represented across five awards totaling $9 million obligated: the National Cancer Institute (three awards), the National Institute of Dental and Craniofacial Research (one award), and the National Institute of Allergy and Infectious Diseases (one award). Activity shows three awards in 2022, one in 2023, and one in 2026, with one award reaching ultimate completion within the next twenty-four months. All work is performed at Kovina's Indianapolis location.
Quick answers
Is Kovina Therapeutics Inc. registered in SAM.gov?
Yes. Kovina Therapeutics Inc.'s SAM.gov registration is active through August 31, 2027.
What is Kovina Therapeutics Inc.'s most recent federal award?
Kovina Therapeutics Inc.'s most recent federal grant award is Novel therapeutics to treat HPV-associated cancers - human papillomaviruses (HPV) cause very common infections of… (R44CA302154), from National Cancer Institute (NIH), on August 14, 2026.
On GovTribe
See Kovina Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors